Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.

MLA

Kosugi, Yusuke, et al. “Antiviral Humoral Immunity against SARS-CoV-2 Omicron Subvariants Induced by XBB.1.5 Monovalent Vaccine in Infection-Naive and XBB-Infected Individuals.” The Lancet. Infectious Diseases, vol. 24, no. 3, Mar. 2024, pp. e147–48. EBSCOhost, https://doi.org/10.1016/S1473-3099(23)00784-3.

APA

Kosugi, Y., Kaku, Y., Hinay, A. A., Jr, Guo, Z., Uriu, K., Kihara, M., Saito, F., Uwamino, Y., Kuramochi, J., Shirakawa, K., Takaori-Kondo, A., & Sato, K. (2024). Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals. The Lancet. Infectious Diseases, 24(3), e147–e148. https://doi.org/10.1016/S1473-3099(23)00784-3

Chicago

Kosugi, Yusuke, Yu Kaku, Alfredo A Hinay Jr, Ziyi Guo, Keiya Uriu, Minoru Kihara, Fumitake Saito, et al. 2024. “Antiviral Humoral Immunity against SARS-CoV-2 Omicron Subvariants Induced by XBB.1.5 Monovalent Vaccine in Infection-Naive and XBB-Infected Individuals.” The Lancet. Infectious Diseases 24 (3): e147–48. doi:10.1016/S1473-3099(23)00784-3.